Lyra Therapeutics shares surge 21.53% intraday following positive Phase 3 ENLIGHTEN 2 trial results for LYR-210 in Chronic Rhinosinusitis.

Lyra Therapeutics (NASDAQ:LYRA) surged 21.53% intraday following positive Phase 3 trial results for its CRS treatment candidate LYR-210, announced on June 2, 2025. The ENLIGHTEN 2 trial achieved statistically significant outcomes for primary and key secondary endpoints, signaling strong therapeutic potential and advancing regulatory pathways. This milestone, coupled with prior enrollment completion of the pivotal trial in October 2024, bolstered investor confidence in the drug’s commercial viability. Earlier news of a registered direct offering in June 2025 had initially pressured the stock, but the trial success overshadowed prior challenges, including manufacturing issues and leadership changes. The intraday rally aligns with the bullish sentiment from the trial data, positioning LYR-210 as a key catalyst for the company’s near-term prospects.